칼슘 채널 차단제 시장 : 약제 종류별, 용도별, 유통 경로별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Calcium Channel Blockers Market with COVID-19 Impact Analysis, By Drug Class, By Application, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,443,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,357,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,724,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 주요 내용

칼슘 채널 차단제 시장 규모는 2022년 140억 510만 달러로 2023년부터 2030년까지 CAGR 6.1%로 확대

칼슘 채널 차단제 시장 - 시장 역학:

• 심혈관 질환의 유병률 증가, 불안장애 및 양극성 장애 환자들에 대한 지원 증가가 예측 기간 동안 성장을 촉진할 것으로 예상됩니다.
• 사람들의 라이프스타일 변화는 심혈관 질환의 유병률 증가로 이어져 칼슘 채널 차단제 시장의 성장을 촉진할 가능성이 높습니다. 이러한 질병은 심장과 혈관에 영향을 미치고 심부전 및 뇌졸중의 위험을 낮추기 위해 칼슘 채널 차단제가 사용됩니다. 또한 심장 질환과 관련된 주요 원인은 종종 혈압 상승이라고 불리는 고혈압입니다. 칼슘 채널 차단제가 고혈압에 효과적이라는 것은 잘 알려져 있습니다. 따라서 심혈관 질환 관리를 개선하기 위해 칼슘 채널 차단제 시장 수요는 꾸준히 증가하고 있습니다. 그러나 두통, 변비, 부종과 같은 칼슘 채널 차단제 관련 부작용은 칼슘 채널 차단제 시장의 세계 수요를 방해할 것으로 예상됩니다. 또한, 칼슘 채널 차단제는 심장 문제가없는 소수의 사람들에게 유리할 수 있습니다. 이와 관련하여 칼슘 채널 차단제는 기분 안정제로 작용하여 불안 장애와 양극성 장애로 고통받는 사람들을 도울 수 있다는 지적도 있습니다. 특히 후자의 경우, 일부 칼슘 채널 차단제는 기존의 기분 안정제나 항정신병 약물에 비해 임산부에게 투여해도 안전한 것으로 알려져 있어 현재 연구 중입니다. 따라서 이러한 요인은 칼슘 채널 차단제 시장을 성장시킬 수 있는 기회로 작용할 수 있습니다.

칼슘 채널 차단제 시장 - 세분화 분석:

• 칼슘 채널 차단제 세계 시장은 약물 종류별, 용도별, 유통 채널별, 지역별로 구분됩니다.
• 약물 종류별로는 디하이드로피리딘, 페닐알킬아민, 벤조티제핀 등 세 가지로 분류됩니다. 디하이드로피리딘 부문이 가장 큰 수익 점유율을 차지할 것으로 보입니다. 이 부문은 R&D 활동의 증가와 제약 산업의 확장으로 인해 기대되는 부문입니다. 또한, 이 약물은 높은 혈관 선택성과 동맥압 및 혈관 저항을 조절하는 능력으로 인해 치료제로서 널리 선호되고 있습니다. 디하이드로피리딘 계열 약물에는 페로디핀, 암로디핀, 니트렌지핀, 니모디핀 등이 있습니다.
• 시장은 용도에 따라 협심증, 고혈압, 비후성 심근증, 부정맥, 기타 등 4가지로 분류됩니다. 가장 큰 시장 점유율을 차지하는 것은 고혈압 부문입니다. 고혈압 부문은 심장, 뇌 및 신장 문제의 위험을 증가시킵니다. 따라서 고혈압 관리에 사용되는 약물에 대한 수요가 증가할 것으로 예상됩니다.
• 이 시장은 유통 채널에 따라 온라인 약국, 병원 약국, 소매 약국 등 세 가지로 분류됩니다. 예측 기간 동안 소매 약국 부문이 시장을 지배할 것으로 보입니다. 건강에 해로운 생활 패턴으로 인해 비만과 심혈관 질환이 증가하고 있습니다. 이에 따라 혈압을 유지하기 위한 약물이 정기적으로 처방되고 있습니다. 또한, 선천성 심장병, 심부전, 고혈압, 심장마비와 같은 심혈관 질환의 증가는 시장에서 풍부하고 대량 소비가 증가함에 따라 소매 약품의 확장을 촉진하고 있습니다.

칼슘 채널 차단제 시장 - 지리적 인사이트:

지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카로 나뉩니다. 이 지역은 비지니스를 가져오는 국가에 따라 더 세분화됩니다.

칼슘 채널 차단제 시장 - 경쟁 상황:

국내 기업과 세계 기업의 존재로 인해 칼슘 채널 차단제 시장은 적당한 경쟁 상태에 있습니다. 주요 기업들은 제휴, 제품 출시, 인수 등 다양한 성장 전략에 초점을 맞추고 있으며, 이는 칼슘 채널 차단제의 세계 성장에 지속적으로 기여하고 있습니다. 또한, 전 세계적으로 심혈관 질환 환자가 증가함에 따라 주요 기업들은 새로운 치료제를 개발하고 시장 지위를 유지하기 위해 많은 투자를 하고 있습니다. 의료 인프라의 발전은 칼슘 채널 차단제에 대한 수요를 증가시키고 있습니다. 예를 들어, 2022년 2월 FDA는 CMP 파마(CMP Pharma)의 Norliqva 경구 용액을 승인했습니다. 이 경구용 용액은 고혈압 치료에 도움이 되며 성인과 6세 어린이의 혈압을 낮추며, 150mL 용량의 Norliqva는 36개월의 사용 기한이 있습니다.

목차

제1장 칼슘 채널 차단제 시장 개요

• 조사 범위
• 시장 추정 연수

제2장 주요 요약

• 시장 내역
• 경쟁 인사이트

제3장 칼슘 채널 차단제 주요 시장 동향

• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 향후 시장 동향

제4장 칼슘 채널 차단제 산업 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 매핑
• 규제 체계 분석

제5장 칼슘 채널 차단제 시장 : COVID-19 감염증의 영향 분석

• 신종 코로나바이러스 감염증 이전의 영향 분석
• 신종 코로나바이러스 감염증 후의 영향 분석

제6장 칼슘 채널 차단제 시장 상황

• 칼슘 채널 차단제 시장 점유율 분석, 2022년
• 주요 제조업체별 내역 데이터
  • 기존 기업 분석
  • 신흥 기업 분석

제7장 칼슘 채널 차단제 시장 - 약제 클래스별

• 개요
  • 약제 클래스별 부문 점유율 분석
  • 디하이드로피리딘
  • 페닐알킬아민
  • 벤조티아제핀

제8장 칼슘 채널 차단제 시장 - 용도별

• 개요
  • 용도별 부문 점유율 분석
  • 협심증
  • 고혈압
  • 비대형 심근증
  • 부정맥
  • 기타

제9장 칼슘 채널 차단제 시장 - 유통 채널별

• 개요
  • 판매 채널별 부문 점유율 분석
  • 온라인 약국
  • 병원 약국
  • 소매 약국

제10장 칼슘 채널 차단제 시장 - 지역별

• 서론
• 북미
  • 개요
  • 북미의 주요 제조업체
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조업체
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아태평양(APAC)
  • 개요
  • 아시아태평양의 주요 제조업체
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 라틴아메리카
  • 개요
  • 라틴아메리카의 주요 제조업체
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조업체
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제11장 주요 벤더 분석 - 칼슘 채널 차단제 업계

• 경쟁 대시보드
• 기업 개요
  • Bayer
  • Sanofi
  • Wyeth-Ayerst
  • ClearSynth
  • AbMole Bioscience
  • Pfizer
  • Lupin Pharmaceuticals, Inc.
  • Searle
  • Knoll Pharmaceuticals
  • GlaxoSmithKline Plc.
  • Aventis
  • AstraZeneca
  • Novartis

제12장 애널리스트의 전방위 전망

ksm

영문 목차

영문목차

REPORT HIGHLIGHT

Calcium Channel Blockers Market size was valued at USD 14,005.1 Million in 2022, expanding at a CAGR of 6.1% from 2023 to 2030.

Calcium channel blockers are known as medications that are utilized to maintain high blood pressure, arrhythmia, and chest pain. Additionally, they can be obtained through prescription and work by relaxing blood vessels and improving the heart's blood and oxygen supply. As a result, this helps to minimize the workload of the heart. Moreover, to treat high blood pressure and angina, it may be prescribed by itself or in conjunction with other medications.

Calcium Channel Blockers Market- Market Dynamics:

• The increasing prevalence rate of cardiovascular diseases and rising assistance to people with anxiety disorders or bipolar disorder is projected to drive growth in the forecast period.

• The changing lifestyle of people has resulted in the increasing prevalence rate of cardiovascular diseases is likely to fuel the calcium channel blocker market growth. As these diseases impact the heart or blood vessels and lower the risk of heart failure & stroke, calcium channel blockers are used. Additionally, the major causes associated with heart disease are hypertension, often referred to as elevated blood pressure. The effectiveness of calcium antagonists in curing this indication has been well documented. This in turn, the demand has been growing steadily for this market for improved management of cardiovascular diseases. However, side effects concerning calcium channel blockers including headache, constipation, and edema are expected to hinder the demand for calcium channel blocker market globally. Moreover, calcium channel blockers may be advantageous to a smaller group of persons who do not have heart issues. In line with this, some indications they may act as mood stabilizers and assist those people who suffer from anxiety disorders or bipolar disorder. The latter is specifically under investigation because some calcium channel blockers may be more secure to administer to pregnant women as compared to most traditional mood stabilizers or antipsychotics. Thus, such factors offer opportunity to increase the growth of the calcium channel blocker market.

Calcium Channel Blockers Market- Key Insights:

• As per the analysis shared by our research analyst, the global calcium channel blocker market is estimated to grow annually at a CAGR of around 6.1% over the forecast period (2023-2030)

• The calcium channel blocker industry is projected to grow at a significant rate due to the increasing prevalence rate of cardiovascular diseases

• Based on drug class segmentation, dihydropyridine was predicted to show maximum market share in the year 2022

• Based on application segmentation, hypertension was the leading type over the forecast period

• On the basis of region, North America was the leading revenue generator in 2022

Calcium Channel Blockers Market- Segmentation Analysis:

• The global calcium channel blockers market is segmented on the basis of drug class, application, distribution channel, and region.

• The market is divided into three categories based on drug class: dihydropyridine, phenylalkylamine, and benzothizepine. The dihydropyridine segment is likely to possess the largest revenue share. The segment is anticipated due to the increasing research & development activities and expansion in the pharmaceutical industry. Moreover, the drug has great vascular selectivity and the capacity to control arterial pressure and vascular resistance, which is widely preferred in therapeutics. Dihydropyridine drugs include felodipine, amlodipine, nitrendipine, and nimodipine.

• The market is divided into four categories based on application: angina, hypertension, hypertrophic cardiomyopathy, arrhythmia, and others. The hypertension segment is expected to hold the largest market share. The hypertension segment raises the risk of heart, brain, and renal problems. Based on this, the demand is likely to increase for drugs used to manage hypertension.

• The market is divided into three categories based on distribution channels: online pharmacies, hospital pharmacies, and retail pharmacies. The retail pharmacies segment is accounted to dominate the market over the forecast period. The unhealthy lifestyle patterns have been resulting in increasing glowing obesity and cardiovascular diseases. As such drugs are prescribed on a regular basis to maintain the blood pressure. Additionally, rising cases of cardiovascular diseases such as congenital heart disease, heart failure, hypertension, and heart attacks are fueling the expansion of retail medicine owing to increase abundance and high consumption in the market.

Calcium Channel Blockers Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Calcium Channel Blockers Market- Competitive Landscape:

The presence of local and global companies makes the calcium channel blocker market moderately competitive. The major players are focusing on numerous growth strategies such as collaborations, product launches, and acquisitions, which are contributing constantly to the growth of the calcium channel blocker globally. Moreover, with the increasing cases of cardiovascular disease across the world, key players are investing amounts to develop new therapeutics and sustain themselves in the market. The improved healthcare infrastructure is raising the demand for the calcium channel blocker. For instance, in February 2022, FDA approved CMP Pharma's Norliqva oral solution. Additionally, the solution helps to treat hypertension, to lower blood pressure in adults & children 6 years of age. Norliqva comes in 150 mL bottles, which have 36-month dating

Recent Developments:

For instance, in May 2021, Milestone Pharmaceuticals, Inc. a biopharmaceutical company released positive topline safety and efficacy data from the Etripamil Phase 3 RAPID clinical trial. Additionally, the company's investigational calcium channel blocker in patients with paroxysmal supraventricular tachycardia (PSVT).

Key features of the study:

• This proposed research study on calcium channel blockers market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year.

• The report provides the client the latest up-to-date and trending insights about the calcium channel blockers market.

• The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for calcium channel blockers market.

• The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the calcium channel blockers market.

• Impact of COVID-19 on calcium channel blockers market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on calcium channel blockers market post-COVID will also be covered.

• In order to give the users of this report a comprehensive view on the calcium channel blockers market, we have also included competitive landscape and key innovator analysis for the calcium channel blockers market.

• The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

• The report offers detailed company profiling featuring major market participants who will help users to understand their financial information and strategic initiatives of players operating in the calcium channel blockers market.

• In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

• The global calcium channel blockers market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CALCIUM CHANNEL BLOCKERS MARKET KEY PLAYERS

• Bayer
• Sanofi
• Wyeth-Ayerst
• ClearSynth
• AbMole Bioscience
• Pfizer
• Lupin Pharmaceuticals, Inc.
• Searle
• Knoll Pharmaceuticals
• GlaxoSmithKline Plc.
• Aventis
• AstraZeneca
• Novartis

GLOBALCALCIUM CHANNEL BLOCKERS MARKET, BY DRUG CLASS

• Dihydropyridine
• Phenylalkylamine
• Benzothizepine

GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY APPLICATION

• Angina
• Hypertension
• Hypertrophic Cardiomyopathy
• Arrhythmia
• Others

GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY DISTRIBUTION CHANNEL

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

GLOBAL CALCIUM CHANNEL BLOCKERS MARKET, BY REGION

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Calcium Channel Blockers Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Calcium Channel Blockers Market Snippet by Drug Class
  • 2.1.2. Calcium Channel Blockers Market Snippet by Application
  • 2.1.3. Calcium Channel Blockers Market Snippet by Distribution Channel
  • 2.1.4. Calcium Channel Blockers Market Snippet by Country
  • 2.1.5. Calcium Channel Blockers Market Snippet by Region
• 2.2. Competitive Insights

3. Calcium Channel Blockers Key Market Trends

• 3.1. Calcium Channel Blockers Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Calcium Channel Blockers Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Calcium Channel Blockers Market Opportunities
• 3.4. Calcium Channel Blockers Market Future Trends

4. Calcium Channel Blockers Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Calcium Channel Blockers Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Calcium Channel Blockers Market Landscape

• 6.1. Calcium Channel Blockers Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Calcium Channel Blockers Market - By Drug Class

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Class, 2022&2030 (%)
  • 7.1.2. Dihydropyridine
  • 7.1.3. Phenylalkylamine
  • 7.1.4. Benzothizepine

8. Calcium Channel Blockers Market - By Application

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Application, 2022&2030 (%)
  • 8.1.2. Angina
  • 8.1.3. Hypertension
  • 8.1.4. Hypertrophic Cardiomyopathy
  • 8.1.5. Arrhythmia
  • 8.1.6. Others

9. Calcium Channel Blockers Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022&2030 (%)
  • 9.1.2. Online Pharmacies
  • 9.1.3. Hospital Pharmacies
  • 9.1.4. Retail Pharmacies

10. Calcium Channel Blockers Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Calcium Channel Blockers Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Calcium Channel Blockers Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Calcium Channel Blockers Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Calcium Channel Blockers Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Calcium Channel Blockers Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Calcium Channel Blockers Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. Bayer
  • 11.2.2. Sanofi
  • 11.2.3. Wyeth-Ayerst
  • 11.2.4. ClearSynth
  • 11.2.5. AbMole Bioscience
  • 11.2.6. Pfizer
  • 11.2.7. Lupin Pharmaceuticals, Inc.
  • 11.2.8. Searle
  • 11.2.9. Knoll Pharmaceuticals
  • 11.2.10. GlaxoSmithKline Plc.
  • 11.2.11. Aventis
  • 11.2.12. AstraZeneca
  • 11.2.13. Novartis

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us

관련자료